Osteosarcoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Osteosarcoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Osteosarcoma - Drugs In Development, 2022, provides an overview of the Osteosarcoma (Oncology) pipeline landscape.
Osteosarcoma is the most common cancer of the bone that destroys tissue and weakens the bone. It is developed from immature bone cells that normally form new bone tissue. Symptoms include pain, bone fractures, swelling, redness and limitation of motion of joints. Risk factors include age, gender, family history and Li-Fraumeni syndrome. Treatment includes chemotherapy and surgery.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Osteosarcoma - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Osteosarcoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Osteosarcoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Osteosarcoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 3, 46, 20, 1, 38 and 8 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 3, 7 and 4 molecules, respectively.
Osteosarcoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Osteosarcoma - Drugs In Development, 2022, provides an overview of the Osteosarcoma (Oncology) pipeline landscape.
Osteosarcoma is the most common cancer of the bone that destroys tissue and weakens the bone. It is developed from immature bone cells that normally form new bone tissue. Symptoms include pain, bone fractures, swelling, redness and limitation of motion of joints. Risk factors include age, gender, family history and Li-Fraumeni syndrome. Treatment includes chemotherapy and surgery.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Osteosarcoma - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Osteosarcoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Osteosarcoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Osteosarcoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 3, 46, 20, 1, 38 and 8 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 3, 7 and 4 molecules, respectively.
Osteosarcoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The pipeline guide provides a snapshot of the global therapeutic landscape of Osteosarcoma (Oncology).
- The pipeline guide reviews pipeline therapeutics for Osteosarcoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Osteosarcoma (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Osteosarcoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Osteosarcoma (Oncology)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Osteosarcoma (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Osteosarcoma (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Osteosarcoma - Overview
Osteosarcoma - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Osteosarcoma - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Osteosarcoma - Companies Involved in Therapeutics Development
Osteosarcoma - Drug Profiles
Osteosarcoma - Dormant Projects
Osteosarcoma - Discontinued Products
Osteosarcoma - Product Development Milestones
Featured News & Press Releases
Apr 11, 2022: Adcendo presents data on uPARAP targeting ADCs in osteosarcoma PDX models at the 2022 AACR Annual Meeting
Jan 27, 2022: OS Therapies announces nationwide open enrollment of remaining 36 to 42 patients in phase IIb trial of OST-HER2 (Listeria monocytogenes) in recurred, resected osteosarcoma
Nov 03, 2021: OS Therapies receives Rare Pediatric Disease Designation (RDD) in osteosarcoma for OST-HER2 (Listeria monocytogenes)
Oct 25, 2021: OS Therapies doses first subject in Phase IIb osteosarcoma therapy trial
Jun 23, 2021: Children's Cancer Research Fund supports AOST-2121 PhIIb clinical trial in recurred, resected osteosarcoma
Apr 26, 2021: Advaxis announces achievement of second milestone under ADXS-HER2 licensing agreement with OS Therapies
Mar 09, 2021: Allarity Therapeutics announces positive data from preclinical study of dovitinib in osteosarcoma
Feb 05, 2021: WPD Pharmaceuticals’ licensor announces 100% survival achieved in osteosarcoma lung metastases animal model of annamycin drug
Feb 02, 2021: Moleculin announces 100% survival achieved in osteosarcoma lung metastases animal model
Jan 26, 2021: OS Therapies receives trial approval from Children's Oncology Group for AOST2121 / OST31-164-01 an open-label Phase 2 study of maintenance therapy with OST31-164 after resection of recurrent osteosarcoma
Jan 19, 2021: Advaxis announces receipt of funding milestone payment under ADXS-HER2 licensing agreement with OS Therapies
Nov 23, 2020: Hillstream BioPharma’s HSB-888 receives rare pediatric disease designation and orphan drug designation for osteosarcoma
Nov 19, 2020: Eisai to present new investigational data on LENVIMA (lenvatinib) in thyroid cancer and osteosarcoma at ESMO Asia 2020
Sep 24, 2020: Innova Therapeutics receives Rare Pediatric Disease Designation from the Food and Drug Administration (FDA) for IVT-8086 for the treatment of Osteosarcoma
Sep 11, 2020: Eisai to present abstracts on lenvatinib mesylate at ESMO Virtual Congress 2020
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Osteosarcoma - Overview
Osteosarcoma - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Osteosarcoma - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Osteosarcoma - Companies Involved in Therapeutics Development
Osteosarcoma - Drug Profiles
Osteosarcoma - Dormant Projects
Osteosarcoma - Discontinued Products
Osteosarcoma - Product Development Milestones
Featured News & Press Releases
Apr 11, 2022: Adcendo presents data on uPARAP targeting ADCs in osteosarcoma PDX models at the 2022 AACR Annual Meeting
Jan 27, 2022: OS Therapies announces nationwide open enrollment of remaining 36 to 42 patients in phase IIb trial of OST-HER2 (Listeria monocytogenes) in recurred, resected osteosarcoma
Nov 03, 2021: OS Therapies receives Rare Pediatric Disease Designation (RDD) in osteosarcoma for OST-HER2 (Listeria monocytogenes)
Oct 25, 2021: OS Therapies doses first subject in Phase IIb osteosarcoma therapy trial
Jun 23, 2021: Children's Cancer Research Fund supports AOST-2121 PhIIb clinical trial in recurred, resected osteosarcoma
Apr 26, 2021: Advaxis announces achievement of second milestone under ADXS-HER2 licensing agreement with OS Therapies
Mar 09, 2021: Allarity Therapeutics announces positive data from preclinical study of dovitinib in osteosarcoma
Feb 05, 2021: WPD Pharmaceuticals’ licensor announces 100% survival achieved in osteosarcoma lung metastases animal model of annamycin drug
Feb 02, 2021: Moleculin announces 100% survival achieved in osteosarcoma lung metastases animal model
Jan 26, 2021: OS Therapies receives trial approval from Children's Oncology Group for AOST2121 / OST31-164-01 an open-label Phase 2 study of maintenance therapy with OST31-164 after resection of recurrent osteosarcoma
Jan 19, 2021: Advaxis announces receipt of funding milestone payment under ADXS-HER2 licensing agreement with OS Therapies
Nov 23, 2020: Hillstream BioPharma’s HSB-888 receives rare pediatric disease designation and orphan drug designation for osteosarcoma
Nov 19, 2020: Eisai to present new investigational data on LENVIMA (lenvatinib) in thyroid cancer and osteosarcoma at ESMO Asia 2020
Sep 24, 2020: Innova Therapeutics receives Rare Pediatric Disease Designation from the Food and Drug Administration (FDA) for IVT-8086 for the treatment of Osteosarcoma
Sep 11, 2020: Eisai to present abstracts on lenvatinib mesylate at ESMO Virtual Congress 2020
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development for Osteosarcoma, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Osteosarcoma - Pipeline by Aadi Bioscience Inc, 2022
Osteosarcoma - Pipeline by Actuate Therapeutics Inc, 2022
Osteosarcoma - Pipeline by ADCendo ApS, 2022
Osteosarcoma - Pipeline by Advanced BioDesign, 2022
Osteosarcoma - Pipeline by Advaxis Inc, 2022
Osteosarcoma - Pipeline by Advenchen Laboratories LLC, 2022
Osteosarcoma - Pipeline by Allarity Therapeutics A/S, 2022
Osteosarcoma - Pipeline by Anagenics Ltd, 2022
Osteosarcoma - Pipeline by AntiCancer Inc, 2022
Osteosarcoma - Pipeline by APEIRON Biologics AG, 2022
Osteosarcoma - Pipeline by API Co Ltd, 2022
Osteosarcoma - Pipeline by Astex Therapeutics Ltd, 2022
Osteosarcoma - Pipeline by AstraZeneca Plc, 2022
Osteosarcoma - Pipeline by Atlanthera, 2022
Osteosarcoma - Pipeline by Aurora BioPharma Inc, 2022
Osteosarcoma - Pipeline by Autolus Therapeutics Plc, 2022
Osteosarcoma - Pipeline by Bayer AG, 2022
Osteosarcoma - Pipeline by Bicycle Therapeutics Plc, 2022
Osteosarcoma - Pipeline by BioAtla Inc, 2022
Osteosarcoma - Pipeline by BioEclipse Therapeutics Inc, 2022
Osteosarcoma - Pipeline by BioMarck Pharmaceuticals Ltd, 2022
Osteosarcoma - Pipeline by BioMed Valley Discoveries Inc, 2022
Osteosarcoma - Pipeline by Boehringer Ingelheim International GmbH, 2022
Osteosarcoma - Pipeline by BrightPath Biotherapeutics Co Ltd, 2022
Osteosarcoma - Pipeline by Bristol-Myers Squibb Co, 2022
Osteosarcoma - Pipeline by CanBas Co Ltd, 2022
Osteosarcoma - Pipeline by Cellectar Biosciences Inc, 2022
Osteosarcoma - Pipeline by Cellestia Biotech AG, 2022
Osteosarcoma - Pipeline by Chia Tai Tianqing Pharmaceutical Group Co Ltd, 2022
Osteosarcoma - Pipeline by CorMedix Inc, 2022
Osteosarcoma - Pipeline by CSPC Pharmaceutical Group Ltd, 2022
Osteosarcoma - Pipeline by Curamir Therapeutics Inc, 2022
Osteosarcoma - Pipeline by Dnatwo Inc, 2022
Osteosarcoma - Pipeline by Eisai Co Ltd, 2022
Osteosarcoma - Pipeline by Eleison Pharmaceuticals LLC, 2022
Osteosarcoma - Pipeline by ENB Therapeutics LLC, 2022
Osteosarcoma - Pipeline by Epeius Biotechnologies Corp, 2022
Osteosarcoma - Pipeline by Exelixis Inc, 2022
Osteosarcoma - Pipeline by GlaxoSmithKline Plc, 2022
Osteosarcoma - Pipeline by GlycoMimetics Inc, 2022
Osteosarcoma - Pipeline by Guangzhou Sinogen Pharmaceutical Co Ltd, 2022
Osteosarcoma - Pipeline by Hebei Senlang Biotechnology Co Ltd, 2022
Osteosarcoma - Pipeline by Hillstream BioPharma Inc, 2022
Osteosarcoma - Pipeline by HRYZ (ShenZhen) Biotech Co, 2022
Osteosarcoma - Pipeline by Hutchison MediPharma Ltd, 2022
Osteosarcoma - Pipeline by Idera Pharmaceuticals Inc, 2022
Osteosarcoma - Pipeline by ImmunityBio Inc, 2022
Osteosarcoma - Pipeline by Incuron, 2022
Osteosarcoma - Pipeline by Innova Therapeutics Inc, 2022
Osteosarcoma - Pipeline by Intezyne Inc, 2022
Osteosarcoma - Pipeline by Iovance Biotherapeutics Inc, 2022
Osteosarcoma - Pipeline by Ipsen SA, 2022
Osteosarcoma - Pipeline by Isofol Medical AB, 2022
Osteosarcoma - Pipeline by Iterion Therapeutics Inc, 2022
Osteosarcoma - Pipeline by ITM Isotopen Technologien Munchen AG, 2022
Osteosarcoma - Pipeline by Jiangsu Hengrui Medicine Co Ltd, 2022
Osteosarcoma - Pipeline by Joint Biosciences Ltd, 2022
Osteosarcoma - Pipeline by K-Group Beta Inc, 2022
Osteosarcoma - Pipeline by Komipharm International Co Ltd, 2022
Osteosarcoma - Pipeline by Kyowa Kirin Co Ltd, 2022
Osteosarcoma - Pipeline by MacroGenics Inc, 2022
Osteosarcoma - Pipeline by Mana Therapeutics Inc, 2022
Osteosarcoma - Pipeline by MD Biosciences GmbH, 2022
Osteosarcoma - Pipeline by MediaPharma SRL, 2022
Osteosarcoma - Pipeline by MedPacto Inc, 2022
Osteosarcoma - Pipeline by Merck & Co Inc, 2022
Osteosarcoma - Pipeline by Merck KGaA, 2022
Osteosarcoma - Pipeline by MetCure Therapeutics LLC, 2022
Osteosarcoma - Pipeline by Moleculin Biotech Inc, 2022
Osteosarcoma - Pipeline by Nanjing Aimeifei Biomedical Technology Co Ltd, 2022
Osteosarcoma - Pipeline by Nkarta Inc, 2022
Osteosarcoma - Pipeline by Novartis AG, 2022
Osteosarcoma - Pipeline by Oncolys BioPharma Inc, 2022
Osteosarcoma - Pipeline by Oncotelic Therapeutics Inc, 2022
Osteosarcoma - Pipeline by Ono Pharmaceutical Co Ltd, 2022
Osteosarcoma - Pipeline by Orgenesis Inc, 2022
Osteosarcoma - Pipeline by OS Therapies LLC, 2022
Osteosarcoma - Pipeline by Peel Therapeutics Inc, 2022
Osteosarcoma - Pipeline by Pfizer Inc, 2022
Osteosarcoma - Pipeline by Pharma Mar SA, 2022
Osteosarcoma - Pipeline by Pimera Inc, 2022
Osteosarcoma - Pipeline by Provectus Biopharmaceuticals Inc, 2022
Osteosarcoma - Pipeline by QSAM Therapeutics Inc, 2022
Osteosarcoma - Pipeline by Radiopharm Theranostics Ltd, 2022
Osteosarcoma - Pipeline by Reven Holdings Inc, 2022
Osteosarcoma - Pipeline by Scancell Holdings Plc, 2022
Osteosarcoma - Pipeline by Secura Bio Inc, 2022
Osteosarcoma - Pipeline by Shanghai De Novo Pharmatech Co Ltd, 2022
Osteosarcoma - Pipeline by Shionogi & Co Ltd, 2022
Osteosarcoma - Pipeline by Singh Biotechnology LLC, 2022
Osteosarcoma - Pipeline by Sorrento Therapeutics Inc, 2022
Osteosarcoma - Pipeline by Taiho Pharmaceutical Co Ltd, 2022
Osteosarcoma - Pipeline by Taithera Inc, 2022
Osteosarcoma - Pipeline by Transcode Therapeutics Inc, 2022
Osteosarcoma - Pipeline by Umoja BioPharma Inc, 2022
Osteosarcoma - Pipeline by United Therapeutics Corp, 2022
Osteosarcoma - Pipeline by Vaccinex Inc, 2022
Osteosarcoma - Pipeline by Veana Therapeutics LLC, 2022
Osteosarcoma - Pipeline by Y-mAbs Therapeutics Inc, 2022
Osteosarcoma - Pipeline by Zentalis Pharmaceuticals Inc, 2022
Osteosarcoma - Dormant Projects, 2022
Osteosarcoma - Discontinued Products, 2022
Number of Products under Development for Osteosarcoma, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Osteosarcoma - Pipeline by Aadi Bioscience Inc, 2022
Osteosarcoma - Pipeline by Actuate Therapeutics Inc, 2022
Osteosarcoma - Pipeline by ADCendo ApS, 2022
Osteosarcoma - Pipeline by Advanced BioDesign, 2022
Osteosarcoma - Pipeline by Advaxis Inc, 2022
Osteosarcoma - Pipeline by Advenchen Laboratories LLC, 2022
Osteosarcoma - Pipeline by Allarity Therapeutics A/S, 2022
Osteosarcoma - Pipeline by Anagenics Ltd, 2022
Osteosarcoma - Pipeline by AntiCancer Inc, 2022
Osteosarcoma - Pipeline by APEIRON Biologics AG, 2022
Osteosarcoma - Pipeline by API Co Ltd, 2022
Osteosarcoma - Pipeline by Astex Therapeutics Ltd, 2022
Osteosarcoma - Pipeline by AstraZeneca Plc, 2022
Osteosarcoma - Pipeline by Atlanthera, 2022
Osteosarcoma - Pipeline by Aurora BioPharma Inc, 2022
Osteosarcoma - Pipeline by Autolus Therapeutics Plc, 2022
Osteosarcoma - Pipeline by Bayer AG, 2022
Osteosarcoma - Pipeline by Bicycle Therapeutics Plc, 2022
Osteosarcoma - Pipeline by BioAtla Inc, 2022
Osteosarcoma - Pipeline by BioEclipse Therapeutics Inc, 2022
Osteosarcoma - Pipeline by BioMarck Pharmaceuticals Ltd, 2022
Osteosarcoma - Pipeline by BioMed Valley Discoveries Inc, 2022
Osteosarcoma - Pipeline by Boehringer Ingelheim International GmbH, 2022
Osteosarcoma - Pipeline by BrightPath Biotherapeutics Co Ltd, 2022
Osteosarcoma - Pipeline by Bristol-Myers Squibb Co, 2022
Osteosarcoma - Pipeline by CanBas Co Ltd, 2022
Osteosarcoma - Pipeline by Cellectar Biosciences Inc, 2022
Osteosarcoma - Pipeline by Cellestia Biotech AG, 2022
Osteosarcoma - Pipeline by Chia Tai Tianqing Pharmaceutical Group Co Ltd, 2022
Osteosarcoma - Pipeline by CorMedix Inc, 2022
Osteosarcoma - Pipeline by CSPC Pharmaceutical Group Ltd, 2022
Osteosarcoma - Pipeline by Curamir Therapeutics Inc, 2022
Osteosarcoma - Pipeline by Dnatwo Inc, 2022
Osteosarcoma - Pipeline by Eisai Co Ltd, 2022
Osteosarcoma - Pipeline by Eleison Pharmaceuticals LLC, 2022
Osteosarcoma - Pipeline by ENB Therapeutics LLC, 2022
Osteosarcoma - Pipeline by Epeius Biotechnologies Corp, 2022
Osteosarcoma - Pipeline by Exelixis Inc, 2022
Osteosarcoma - Pipeline by GlaxoSmithKline Plc, 2022
Osteosarcoma - Pipeline by GlycoMimetics Inc, 2022
Osteosarcoma - Pipeline by Guangzhou Sinogen Pharmaceutical Co Ltd, 2022
Osteosarcoma - Pipeline by Hebei Senlang Biotechnology Co Ltd, 2022
Osteosarcoma - Pipeline by Hillstream BioPharma Inc, 2022
Osteosarcoma - Pipeline by HRYZ (ShenZhen) Biotech Co, 2022
Osteosarcoma - Pipeline by Hutchison MediPharma Ltd, 2022
Osteosarcoma - Pipeline by Idera Pharmaceuticals Inc, 2022
Osteosarcoma - Pipeline by ImmunityBio Inc, 2022
Osteosarcoma - Pipeline by Incuron, 2022
Osteosarcoma - Pipeline by Innova Therapeutics Inc, 2022
Osteosarcoma - Pipeline by Intezyne Inc, 2022
Osteosarcoma - Pipeline by Iovance Biotherapeutics Inc, 2022
Osteosarcoma - Pipeline by Ipsen SA, 2022
Osteosarcoma - Pipeline by Isofol Medical AB, 2022
Osteosarcoma - Pipeline by Iterion Therapeutics Inc, 2022
Osteosarcoma - Pipeline by ITM Isotopen Technologien Munchen AG, 2022
Osteosarcoma - Pipeline by Jiangsu Hengrui Medicine Co Ltd, 2022
Osteosarcoma - Pipeline by Joint Biosciences Ltd, 2022
Osteosarcoma - Pipeline by K-Group Beta Inc, 2022
Osteosarcoma - Pipeline by Komipharm International Co Ltd, 2022
Osteosarcoma - Pipeline by Kyowa Kirin Co Ltd, 2022
Osteosarcoma - Pipeline by MacroGenics Inc, 2022
Osteosarcoma - Pipeline by Mana Therapeutics Inc, 2022
Osteosarcoma - Pipeline by MD Biosciences GmbH, 2022
Osteosarcoma - Pipeline by MediaPharma SRL, 2022
Osteosarcoma - Pipeline by MedPacto Inc, 2022
Osteosarcoma - Pipeline by Merck & Co Inc, 2022
Osteosarcoma - Pipeline by Merck KGaA, 2022
Osteosarcoma - Pipeline by MetCure Therapeutics LLC, 2022
Osteosarcoma - Pipeline by Moleculin Biotech Inc, 2022
Osteosarcoma - Pipeline by Nanjing Aimeifei Biomedical Technology Co Ltd, 2022
Osteosarcoma - Pipeline by Nkarta Inc, 2022
Osteosarcoma - Pipeline by Novartis AG, 2022
Osteosarcoma - Pipeline by Oncolys BioPharma Inc, 2022
Osteosarcoma - Pipeline by Oncotelic Therapeutics Inc, 2022
Osteosarcoma - Pipeline by Ono Pharmaceutical Co Ltd, 2022
Osteosarcoma - Pipeline by Orgenesis Inc, 2022
Osteosarcoma - Pipeline by OS Therapies LLC, 2022
Osteosarcoma - Pipeline by Peel Therapeutics Inc, 2022
Osteosarcoma - Pipeline by Pfizer Inc, 2022
Osteosarcoma - Pipeline by Pharma Mar SA, 2022
Osteosarcoma - Pipeline by Pimera Inc, 2022
Osteosarcoma - Pipeline by Provectus Biopharmaceuticals Inc, 2022
Osteosarcoma - Pipeline by QSAM Therapeutics Inc, 2022
Osteosarcoma - Pipeline by Radiopharm Theranostics Ltd, 2022
Osteosarcoma - Pipeline by Reven Holdings Inc, 2022
Osteosarcoma - Pipeline by Scancell Holdings Plc, 2022
Osteosarcoma - Pipeline by Secura Bio Inc, 2022
Osteosarcoma - Pipeline by Shanghai De Novo Pharmatech Co Ltd, 2022
Osteosarcoma - Pipeline by Shionogi & Co Ltd, 2022
Osteosarcoma - Pipeline by Singh Biotechnology LLC, 2022
Osteosarcoma - Pipeline by Sorrento Therapeutics Inc, 2022
Osteosarcoma - Pipeline by Taiho Pharmaceutical Co Ltd, 2022
Osteosarcoma - Pipeline by Taithera Inc, 2022
Osteosarcoma - Pipeline by Transcode Therapeutics Inc, 2022
Osteosarcoma - Pipeline by Umoja BioPharma Inc, 2022
Osteosarcoma - Pipeline by United Therapeutics Corp, 2022
Osteosarcoma - Pipeline by Vaccinex Inc, 2022
Osteosarcoma - Pipeline by Veana Therapeutics LLC, 2022
Osteosarcoma - Pipeline by Y-mAbs Therapeutics Inc, 2022
Osteosarcoma - Pipeline by Zentalis Pharmaceuticals Inc, 2022
Osteosarcoma - Dormant Projects, 2022
Osteosarcoma - Discontinued Products, 2022
LIST OF FIGURES
Number of Products under Development for Osteosarcoma, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Top 10 Routes of Administration, 2022
Number of Products by Stage and Top 10 Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022
Number of Products under Development for Osteosarcoma, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Top 10 Routes of Administration, 2022
Number of Products by Stage and Top 10 Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022
